Modafinil and nicotine interactions in abstinent smokers

Human Psychopharmacology

Volumn 23, Issue 1, 2008, Pages 21-30

  Sofuoglu, Mehmet ^a   Waters, Andrew J ^b   Mooney, Marc ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Modafinil; Nicotine; Nicotine withdrawal

Indexed keywords

COMMIT; MODAFINIL; NICOTINE; PLACEBO; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MECHANISM; FATIGUE; FEMALE; HUMAN; LOZENGE; MALE; MONOTHERAPY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROFILE OF MOOD STATES; REACTION TIME; SELF REPORT; SINGLE DRUG DOSE; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TASK PERFORMANCE; TOBACCO DEPENDENCE; WAKEFULNESS; WITHDRAWAL SYNDROME;

ADULT; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HEART RATE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; NICOTINE; NICOTINIC AGONISTS; PAIN MEASUREMENT; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 38649141199     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.878     Document Type: Article

References (46)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. American Psychiatric Association: Washington, DC.
2. al'Absi M, Amunrud T, Wittmers LE. 2002. Psychophysiological effects of nicotine abstinence and behavioral challenges in habitual smokers. Pharmacol Biochem Behav 72: 707-716.
3. Ballon JS, Feifel D. 2006. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 67: 554-566.
4. Baranski JV, Pigeau R, Dinich P, Jacobs I. 2004. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 19: 323-332.
5. Brandon TH, Tiffany ST, Obremski KM, Baker TB. 1990. Post-cessation cigarette use: the process of relapse. Addict Behav 15: 105-114.
6. Choi JH, Dresler CM, Norton MR, Strahs KR. 2003. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 5: 635-644.
7. Cohen J. 1988. Statistical Power Analysis for the Behavioral Sciences. L. Erlbaum Associates: Hillsdale, N.J.
8. Cox LS, Tiffany ST, Christen AG. 2001. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res 3: 7-16.
9. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. 2005. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30: 205-211.
10. Dackis CA, Lynch KG, Yu E, et al. 2003. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 70: 29-37.
11. DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. 2004. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol 24: 87-90.
12. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K. 1998. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 253: 135-138.
13. Ferraro L, Antonelli T, Tanganelli S, et al. 1999. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 20: 346-356.
14. Gill M, Haerich P, Westcott K, Godenick KL, Tucker JA. 2006. Cognitive performance following modafinil versus placebo in sleep-deprived emergency physicians: a double-blind randomized crossover study. Acad Emerg Med 13: 158-165.
15. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW. 2007. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology.
16. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. 1991. The Fagerstrom Test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire. Br J Addictions 86: 1119-1127.
17. Hogarty KY, Kromrey JD. 2003. RETR_PWR: an SAS macro for retrospective statistical power analysis. Behav Res Methods Instrum Comput 35: 585-589.
18. Houtsmuller EJ, Henningfield JE, Stitzer ML. 2003. Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology (Berl) 167: 20-27.
19. Hughes JC, Cook CC. 1997. The efficacy of disulfiram: a review of outcome studies. Addiction 92: 381-395.
20. Hughes JR, Hatsukami D. 1986. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43: 289-294.
21. Kassel JD, Shiffman S. 1997. Attentional mediation of cigarette smoking's effect on anxiety. Health Psychol 16: 359-368.
22. Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. 1994. Predicting smoking cessation. Who will quit with and without the nicotine patch. Jama 271: 589-594.
23. Kotlyar M, Mendoza-Baumgart MI, Li ZZ, et al. 2007. Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. Tob Control 16: 138-142.
24. Kucera H, Francis WN. 1967. Computational Analysis of Present Day American English. Brown University Press: Providence, RI.
25. MacDonald JR, Hill JD, Tarnopolsky MA. 2002. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 59: 1876-1880.
26. Madras BK, Xie Z, Lin Z, et al. 2006. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319: 561-569.
27. Malcolm R, Swayngim K, Donovan JL, et al. 2006. Modafinil and cocaine interactions. Am J Drug Alcohol Abuse 32: 577-587.
28. Manly T, Lewis GH, Robertson IH, Watson PC, Datta AK. 2002. Coffee in the cornflakes: time-of-day as a modulator of executive response control. Neuropsychologia 40: 1-6.
29. McNair D, Lorr M, Dropperman L. 1971. Manual for Profile of Mood States. Educational and industrial testing services: San Diego, CA.
30. Muller U, Steffenhagen N, Regenthal R, Bublak P. 2004. Effects of modafinil on working memory processes in humans. Psychopharmacology (Berl) 77: 161-169.
31. Murillo-Rodriguez E, Haro R, Palomero-Rivero M, Millan-Aldaco D, Drucker-Colin R. 2007. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res 176: 353-357.
32. Pich EM, Pagliusi SR, Tessari M, Talabot-Ayer D, Hooft van Huijsduijnen R, Chiamulera C. 1997. Common neural substrates for the addictive properties of nicotine and cocaine. Science 275: 83-86.
33. Randall DC, Fleck NL, Shneerson JM, File SE. 2004. The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers. Pharmacol Biochem Behav 77: 547-555.
34. Randall DC, Viswanath A, Bharania P, et al. 2005. Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived? J Clin Psychopharmacol 25: 175-179.
35. Robertson IH, Manly T, Andrade J, Baddeley BT, Yiend J. 1997. 'Oops!': performance correlates of everyday attentional failures in traumatic brain injured and normal subjects. Neuropsychologia 35: 747-758.
36. Robertson P, Jr., Hellriegel ET. 2003. Clinical pharmacokinetic profile of modafinil. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 42: 123-137.
37. Rush CR, Kelly TH, Hays LR, Baker RW, Wooten AF. 2002. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol 13: 105-115.
38. Schneider W, Eschman A, Zuccolotto A. 2002. E-Prime User's Guide Pittsburgh. Psychology Software Tools, Inc.: Pittsburgh.
39. Sofuoglu M, Mouratidis M, Yoo S, Kosten T. 2006. Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers. Behav Pharmacol 17: 731-735.
40. Taneja I, Diedrich A, Black BK, Byrne DW, Paranjape SY, Robertson D. 2005. Modafinil elicits sympathomedullary activation. Hypertension 45: 612-618.
41. Taneja I, Haman K, Shelton RC, Robertson D. 2007. A randomized, double-blind, crossover trial of modafinil on mood. J Clin Psychopharmacol 27: 76-79.
42. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. 2003. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 165: 260-269.
43. Waters AJ, Sayette MA. 2005. In Handbook on Implicit Cognition and Addiction, Wiers RW, Stacy AW) (eds), Sage: Thousand Oaks, CA; 309-338,
44. Watson D, Clark LA, Tellegen A. 1988. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54: 1063-1070.
45. Wesensten NJ. 2006. Effects of modafinil on cognitive performance and alertness during sleep deprivation. Curr Pharm Des 12: 2457-2471.
46. Wesensten NJ, Belenky G, Kautz MA, Thorne DR, Reichardt RM, Balkin TJ. 2002. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology (Berl) 159: 238-247.